Eli Lilly’s surprise Lartruvo failure, Loxo buy put a dent in its 2019 hopes

6th February 2019 Uncategorised 0

Cancer drug Lartruvo’s shocking clinical trial failure, coupled with disappointing sales of drugs like Verzenio, prompted a cut into the higher-than-expected 2019 projections Lilly rolled out in December. And that put executives on the spot Wednesday as analysts pressed for answers.

More: Eli Lilly’s surprise Lartruvo failure, Loxo buy put a dent in its 2019 hopes
Source: fierce